Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) and their connected person, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Share Sale Price: £11.33 per Ordinary share.
- Transaction Date: February 23, 2009.
Material Changes
The filing details a change in shareholding for Mrs. Claudine Bruck Slaoui, a connected person of Dr. M. M. Slaoui (PDMR). The transaction involved the sale of shares to meet tax liabilities following the vesting of a Share Value Plan award. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a director-related transaction under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Dr. M. M. Slaoui is a Person Discharging Managerial Responsibility at GSK Plc.
- Mrs. Claudine Bruck Slaoui (connected person) sold 355 Ordinary shares on February 23, 2009.
- The sale price was £11.33 per share.
- The purpose of the sale was to meet tax liabilities from a Share Value Plan award.
- Following the sale, 845 shares were retained from an initial award of 1,200 shares.